The clinical outcomes of Polivy (generic name: polatuzumab vedotin) were measured through several methods, primarily focusing on its efficacy and safety in treating certain types of cancer. Polivy is a medication used in combination with other drugs to treat diffuse large B-cell lymphoma (DLBCL), a type of non-Hodgkin lymphoma.

The clinical trials for Polivy primarily focused on assessing its impact on overall response rate (ORR), complete response rate (CR), progression-free survival (PFS), and overall survival (OS).

1. Overall Response Rate (ORR) - This measures the percentage of patients who experience a tumor size reduction following treatment.
2. Complete Response Rate (CR) - Also known as complete remission, this measures the percentage of patients who experience the disappearance of all signs of cancer following treatment.
3. Progression-Free Survival (PFS) - This measures the length of time during and after treatment that patients live with the disease without it worsening.
4. Overall Survival (OS) - This measures the length of time from either the date of diagnosis or the start of treatment that patients are still alive.

In addition to these measures, the safety and tolerability of Polivy were also assessed by monitoring adverse events (side effects) and serious adverse events (serious side effects) throughout the clinical trials.

Sources:
[1] <https://www.drugpatentwatch.com/drugs/polivy>